10-Q 1 form10q.txt FORM 10-Q SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended September 30, 2002; or [ ] Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from _________ to _________. Commission File Number 1-10315 ------- HEALTHSOUTH CORPORATION ------------------------------------------------------------ (Exact Name of Registrant as Specified in its Charter) Delaware 63-0860407 ------------------------------- ----------------- (State or Other Jurisdiction of (I.R.S. Employer Incorporation or Organization) Identification No.) ONE HEALTHSOUTH PARKWAY, BIRMINGHAM, ALABAMA 35243 ------------------------------------------------------- (Address of Principal Executive Offices) (Zip Code) (205) 967-7116 -------------- (Registrant's Telephone Number, Including Area Code) Indicate by check mark whether the Registrant (1) has filed all Reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such Reports), and (2) has been subject to such filing requirements for the past 90 days. YES X NO ----- ----- Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date. Class Outstanding at November 12, 2002 ----------------------- --------------------------------- COMMON STOCK, PAR VALUE 396,427,172 SHARES $.01 PER SHARE HEALTHSOUTH CORPORATION AND SUBSIDIARIES INDEX PART I -- FINANCIAL INFORMATION
Page ---- Item 1. Financial Statements Consolidated Balance Sheets -- September 30, 2002 (Unaudited) and December 31, 2001 3 Consolidated Statements of Income (Unaudited) -- Three Months and Nine Months Ended September 30, 2002 and 2001 5 Consolidated Statements of Cash Flows (Unaudited) -- Nine Months Ended September 30, 2002 and 2001 6 Notes to Consolidated Financial Statements (Unaudited) -- Three Months and Nine Months Ended September 30, 2002 and 2001 8 Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 16 Item 3. Quantitative and Qualitative Disclosures about Market Risk 23 Item 4. Controls and Procedures 24 PART II -- OTHER INFORMATION Item 1. Legal Proceedings 25 Item 2. Changes in Securities and Use of Proceeds 27 Item 6. Exhibits and Reports on Form 8-K 28
Page 2 PART I -- FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS HEALTHSOUTH CORPORATION AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (IN THOUSANDS)
SEPTEMBER 30, DECEMBER 31, 2002 2001 ------------- ------------ (Unaudited) ASSETS CURRENT ASSETS Cash and cash equivalents $ 389,367 $ 276,583 Other marketable securities 1,074 1,873 Accounts receivable--net 1,028,562 940,414 Inventories, prepaid expenses and other current assets 440,567 438,295 Income tax refund receivable 24,881 79,290 ------------- ------------ TOTAL CURRENT ASSETS 1,884,451 1,736,455 OTHER ASSETS 326,734 342,943 PROPERTY, PLANT AND EQUIPMENT--NET 3,067,666 2,774,736 GOODWILL--NET 2,552,232 2,630,530 INTANGIBLE ASSETS--NET 99,382 94,573 ------------- ------------ TOTAL ASSETS $ 7,930,465 $ 7,579,237 ============= ============
Page 3 HEALTHSOUTH CORPORATION AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (CONTINUED) (IN THOUSANDS)
SEPTEMBER 30, DECEMBER 31, 2002 2001 ------------- ----------- LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable $ 30,738 $ 37,085 Salaries and wages payable 56,499 65,364 Deferred income taxes 94,288 99,873 Accrued interest payable and other liabilities 149,968 134,762 Current portion of long-term debt 376,112 21,912 ------------- ----------- TOTAL CURRENT LIABILITIES 707,605 358,996 LONG-TERM DEBT 2,835,699 3,005,035 DEFERRED INCOME TAXES 257,007 259,535 DEFERRED REVENUE AND OTHER LONG-TERM LIABILITIES 4,654 4,206 MINORITY INTERESTS--LIMITED PARTNERSHIPS 161,579 154,541 STOCKHOLDERS' EQUITY: Preferred Stock, $.10 par value--1,500,000 shares authorized; issued and outstanding--none -- -- Common Stock, $.01 par value--600,000,000 shares authorized; 438,068,000 and 430,422,000 shares issued at September 30, 2002 and December 31, 2001, respectively 4,381 4,304 Additional paid-in capital 2,712,516 2,657,804 Accumulated other comprehensive income 252 16,607 Retained earnings 1,565,675 1,430,846 Treasury stock, at cost; 42,680,000 shares at September 30, 2002 and 38,742,000 shares at December 31, 2001 (313,719) (280,524) Receivable from Employee Stock Ownership Plan (1,405) (2,699) Notes receivable from stockholders, officers and management employees (3,779) (29,414) ------------- ----------- TOTAL STOCKHOLDERS' EQUITY 3,963,921 3,796,924 ------------- ----------- TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $7,930,465 $7,579,237 ============= ============
See accompanying notes. Page 4 HEALTHSOUTH CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED - IN THOUSANDS, EXCEPT PER SHARE DATA)
THREE MONTHS ENDED NINE MONTHS ENDED SEPTEMBER 30, SEPTEMBER 30, -------------- -- --------------- -------------- -- -------------- 2002 2001 2002 2001 -------------- --------------- -------------- -------------- Revenues $ 1,093,785 $ 1,075,874 $ 3,387,243 $ 3,265,324 Operating unit expenses 786,947 714,750 2,270,760 2,173,500 Corporate general and administrative expenses 55,125 38,958 138,382 122,827 Provision for doubtful accounts 23,898 23,980 74,534 83,221 Depreciation and amortization 79,505 95,790 236,894 280,231 Early extinguishment of debt (25,078) -- (19,544) 6,475 Loss on sale of assets -- -- 76,690 139,883 Interest expense 57,972 50,914 158,907 165,580 Interest income (1,938) (1,430) (4,205) (5,742) -------------- --------------- -------------- -------------- 976,431 922,962 2,932,418 2,965,975 -------------- --------------- -------------- -------------- Income before income taxes, minority interests and cumulative effect of accounting change 117,354 152,912 454,825 299,349 Provision for income taxes 33,919 51,659 147,869 93,193 -------------- --------------- -------------- -------------- Income before minority interests and cumulative effect of accounting change 83,435 101,253 306,956 206,156 Minority interests (29,821) (22,127) (88,087) (71,667) -------------- --------------- -------------- -------------- Income before cumulative effect of accounting change 53,614 79,126 218,869 134,489 Cumulative effect of accounting change, net of tax (Note 7) -- -- (83,165) -- -------------- --------------- -------------- -------------- Net income $ 53,614 $ 79,126 $ 135,704 $ 134,489 ============== =============== ============== ============== Weighted average common shares outstanding 397,237 390,455 394,867 389,135 ============== =============== ============== ============== Income per common share before cumulative effect of accounting change $ 0.13 $ 0.20 $ 0.55 $ 0.35 Cumulative effect of accounting change -- -- (0.21) -- -------------- --------------- -------------- -------------- Net income per common share $ 0.13 $ 0.20 $ 0.34 $ 0.35 ============== =============== ============== ============== Weighted average common shares outstanding -- assuming dilution 399,352 401,074 400,334 399,077 ============== =============== ============== ============== Income per common share before cumulative effect of accounting change -- assuming dilution $ 0.13 $ 0.20 $ 0.55 $ 0.34 Cumulative effect of accounting change -- -- (0.21) -- -------------- --------------- -------------- -------------- Net income per common share -- assuming dilution $ 0.13 $ 0.20 $ 0.34 $ 0.34 ============== =============== ============== ==============
See accompanying notes. Page 5 HEALTHSOUTH CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED - IN THOUSANDS)
NINE MONTHS ENDED SEPTEMBER 30, ---------------- -- ---------------- 2002 2001 ---------------- ---------------- OPERATING ACTIVITIES Net income $ 135,704 $ 134,489 Adjustments to reconcile net income to net cash provided by operating activities: Cumulative effect of accounting change 115,042 -- Depreciation and amortization 236,894 280,231 Provision for doubtful accounts 74,534 83,221 Equity-based compensation (724) 4,281 Income applicable to minority interests of limited partnerships 88,087 71,667 Loss on sale of assets 76,690 139,883 Gain on extinguishment of debt (25,078) -- Impairment charges 5,534 6,475 Provision for deferred income taxes 18,382 44,442 Changes in operating assets and liabilities, net of effects of acquisitions: Accounts receivable (177,886) (82,068) Inventories, prepaid expenses and other current assets 50,459 (94,253) Accounts payable and accrued expenses (1,856) (179,684) -------- -------- NET CASH PROVIDED BY OPERATING ACTIVITIES 595,782 408,684 INVESTING ACTIVITIES Purchases of property, plant and equipment (560,425) (287,535) Proceeds from sale of non-strategic assets 12,272 103,498 Additions to intangible assets, net of effects of acquisitions (69,809) (41,384) Assets obtained through acquisitions, net of liabilities assumed (16,907) (5,031) Purchase of limited partnership units (26,147) (21,708) Changes in other assets (1,010) (56,816) Proceeds from sale of marketable securities 799 -- Investments in other marketable securities -- (2,096) -------- -------- NET CASH USED IN INVESTING ACTIVITIES (661,227) (311,072)
Page 6 HEALTHSOUTH CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED) (UNAUDITED - IN THOUSANDS)
NINE MONTHS ENDED SEPTEMBER 30, ---------------- -- ---------------- 2002 2001 ---------------- ---------------- FINANCING ACTIVITIES Proceeds from borrowings $ 1,642,578 $ 1,667,000 Principal payments on long-term debt (1,432,636) (1,770,657) Proceeds from exercise of options 31,087 39,465 Purchase of treasury stock (33,195) -- Reduction in receivable from Employee Stock Ownership Plan 1,294 2,716 Decrease in loans to stockholders 25,635 4,806 Proceeds from investment by minority interests -- 20,946 Payment of cash distributions to limited partners (54,902) (54,099) Foreign currency translation adjustment (1,632) 2,770 ---------------- ---------------- NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES 178,229 (87,053) ---------------- ---------------- INCREASE IN CASH AND CASH EQUIVALENTS 112,784 10,559 Cash and cash equivalents at beginning of period 276,583 180,317 ---------------- ---------------- CASH AND CASH EQUIVALENTS AT END OF PERIOD $ 389,367 $ 190,876 ================ ================ SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION Cash paid during the year for: Interest $ 123,072 $ 153,822 Income taxes 38,653 33,434
See accompanying notes. Page 7 HEALTHSOUTH CORPORATION AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) THREE MONTHS AND NINE MONTHS ENDED SEPTEMBER 30, 2002 AND 2001 NOTE 1 -- The accompanying consolidated financial statements include the accounts of HEALTHSOUTH Corporation (the "Company") and its subsidiaries. This information should be read in conjunction with the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2001. It is management's opinion that the accompanying consolidated financial statements reflect all adjustments (which are normal recurring adjustments, except as otherwise indicated) necessary for a fair presentation of the results for the interim period and the comparable period presented. NOTE 2 -- The Company had a $1,750,000,000 revolving credit facility with Bank of America, N.A. and other participating banks (the "1998 Credit Agreement"). Interest on the 1998 Credit Agreement was paid based on LIBOR plus a predetermined margin, a base rate, or competitively bid rates from the participating banks. The Company was required to pay a fee based on the unused portion of the revolving credit facility ranging from 0.09% to 0.25%, depending on certain defined ratios. The Company recorded a loss of $5,534,000 in the second quarter of 2002 related to the write-off of the unamortized balance of loan fees on the 1998 Credit Agreement, which was terminated in June 2002. On June 14, 2002, the Company entered into a five-year, $1,250,000,000 revolving credit facility (the "2002 Credit Agreement"), which replaced the 1998 Credit Agreement. Interest on the 2002 Credit Agreement is paid based on LIBOR plus a predetermined margin or a base rate. The Company is required to pay a fee based on the unused portion of the revolving credit facility ranging from .275% to .500% depending on the Company's debt ratings. The principal amount is payable in full on June 14, 2007. The Company has provided a negative pledge on all assets under the 2002 Credit Agreement. The effective interest rate on the average outstanding balance under the 2002 Credit Agreement was 3.26% for the nine months ended September 30, 2002, compared to the average prime rate of 4.75% during the same period. At September 30, 2002, we had drawn $150,000,000 under the 2002 Credit Agreement. On March 20, 1998, the Company issued $500,000,000 in 3.25% Convertible Subordinated Debentures due 2003 (the "3.25% Convertible Debentures") in a private placement. An additional $67,750,000 principal amount of the 3.25% Convertible Debentures was issued on March 31, 1998 to cover underwriters' overallotments. Interest is payable on April 1 and October 1. The 3.25% Convertible Debentures are convertible into common stock of the Company at the option of the holder at a conversion price of $36.625 per share. The conversion price is subject to adjustment upon the occurrence of (a) a subdivision, combination or reclassification of outstanding shares of common stock, (b) the payment of a stock dividend or stock distribution on any shares of the Company's capital stock, (c) the issuance of rights or warrants to all holders of common stock entitling them to purchase shares of common stock at less than the current market price, or (d) the payment of certain other distributions with respect to the Company's common stock. In addition, the Company may, from time to time, lower the conversion price for periods of not less than 20 days, in its discretion. The net proceeds from the issuance of the 3.25% Convertible Debentures were used by the Company to pay down indebtedness outstanding under its then-existing credit facilities. The 3.25% Convertible Debentures mature on April 1, 2003. On June 22, 1998, the Company issued $250,000,000 in 6.875% Senior Notes due 2005 and $250,000,000 in 7.0% Senior Notes due 2008 (collectively, the "Senior Notes"). Interest is payable on June 15 and December 15. The Senior Notes are unsecured, unsubordinated obligations of the Company. The net proceeds from the issuance of the Senior Notes were used by the Company to Page 8 pay down indebtedness outstanding under its then-existing credit facilities. The Senior Notes mature on June 15, 2005 and June 15, 2008. On September 25, 2000, the Company issued $350,000,000 in 10-3/4% Senior Subordinated Notes due 2008 (the "10-3/4% Notes"). Interest is payable on April 1 and October 1. The 10-3/4% Notes are senior subordinated obligations of the Company and, as such, are subordinated to all existing and future senior indebtedness of the Company, and also are effectively subordinated to all existing and future liabilities of the Company's subsidiaries and partnerships. The net proceeds from the issuance of the 10-3/4% Notes were used by the Company to redeem its then-outstanding 9.5% Senior Notes due 2001 and to pay down indebtedness outstanding under its then-existing credit facilities. The 10-3/4% Notes mature on October 1, 2008. On February 1, 2001, the Company issued $375,000,000 in 8-1/2% Senior Notes due 2008 (the "8-1/2% Notes"). Interest is payable on February 1 and August 1. The 8-1/2% Notes are unsecured, unsubordinated obligations of the Company. The net proceeds from the issuance of the 8-1/2% Notes were used to pay down indebtedness outstanding under the Company's credit facilities. The 8-1/2% Notes mature on February 1, 2008. On September 28, 2001, the Company issued $400,000,000 in 8-3/8% Senior Notes due 2011 (the "8-3/8% Notes"). Interest is payable on April 1 and October 1. The 8-3/8% Notes are unsecured, unsubordinated obligations of the Company. The net proceeds from the issuance of the 8-3/8% Notes were used to pay down indebtedness outstanding under the Company's credit facilities. The 8-3/8% Notes mature on October 1, 2011. On September 28, 2001, the Company issued $200,000,000 in 7-3/8% Senior Notes due 2006 (the "7-3/8% Notes"). Interest is payable on April 1 and October 1. The 7-3/8% Notes are unsecured, unsubordinated obligations of the Company. The net proceeds from the issuance of the 7-3/8% Notes were used to pay down indebtedness outstanding under the Company's credit facilities. The 7-3/8% Notes mature on October 1, 2006. On May 17, 2002, the Company issued $1,000,000,000 in 7-5/8% Senior Notes due 2012 (the "7-5/8% Notes"). Interest is payable on June 1 and December 1. The 7-5/8% Notes are unsecured, unsubordinated obligations of the Company. The net proceeds from the issuance of the 7-5/8% Notes were used to pay down indebtedness outstanding under the Company's credit facilities and for other corporate purposes. The 7-5/8% Notes mature on June 1, 2012. Page 9 At September 30, 2002, and December 31, 2001, long-term debt consisted of the following:
September 30, December 31, 2002 2001 ----------------- --------------- (In thousands) Advances under a $1,250,000,000 credit agreement with banks $ 150,000 $ 540,000 3.25% Convertible Subordinated Debentures due 2003 354,150 567,750 6.875% Senior Notes due 2005 245,000 250,000 7-3/8% Senior Notes due 2006 180,300 200,000 7.0% Senior Notes due 2008 250,000 250,000 10-3/4% Senior Subordinated Notes due 2008 319,260 350,000 8-1/2% Senior Notes due 2008 343,000 375,000 8-3/8% Senior Notes due 2011 347,700 400,000 7-5/8% Senior Notes due 2012 931,650 -- Other long-term debt 90,751 94,197 ----------------- --------------- 3,211,811 3,026,947 Less amounts due within one year 376,112 21,912 ----------------- --------------- $2,835,699 $3,005,035 ================= ===============
During 1995 and 1998, the Company entered into two tax retention operating lease agreements structured through financial institutions for its corporate headquarters building and for nine of its rehabilitation hospitals. In December 2001, the Company entered into a seven-and-one-half year operating lease agreement to provide for the financing of a replacement medical center in Birmingham, Alabama. On May 29, 2002, the Company exercised its option to purchase the properties financed under these leases. The total purchase price of these properties was approximately $207,109,000. The 7-5/8% Senior Notes reflect a deferred benefit of $22,950,000 related to the early termination of an interest rate swap. This benefit will be amortized as a reduction to interest expense over the remaining term of the notes. Effective April 1, 2002, the Company adopted the provisions of FASB Statement No. 145. NOTE 3 -- During the first nine months of 2002, the Company acquired two outpatient rehabilitation facilities, one outpatient diagnostic center and one surgery center. The total purchase price of these acquired facilities was approximately $16,906,000. The Company also entered into non-compete agreements totaling approximately $2,900,000 in connection with these transactions. The cost in excess of the acquired facilities' net asset value was approximately $15,547,000. The results of operations (not material individually or in the aggregate) of these acquisitions are included in the consolidated financial statements from their respective acquisition dates. NOTE 4 -- During 1998, the Company recorded impairment and restructuring charges related to the Company's decision to close certain facilities that did not fit with the Company's strategic vision, underperforming facilities and facilities not located in target markets (the "Fourth Quarter 1998 Charge"). Approximately 98% of the locations identified in the Fourth Quarter 1998 Charge have been closed. Page 10 Details of the impairment and restructuring charge activity through the first nine months of 2002 are as follows:
Activity -------- Balance at Cash Non-Cash Balance at Description 12/31/01 Payments Impairments 09/30/02 -------------------------------------------------------------------------------------------- (In thousands) Fourth Quarter 1998 Charge: Lease abandonment costs $ 9,465 $ 5,396 $ -- $ 4,069 --------------------------------------------------------- Total Fourth Quarter 1998 Charge $ 9,465 $ 5,396 $ -- $ 4,069 =========================================================
The remaining balance at September 30, 2002 is included in accrued interest payable and other liabilities in the accompanying balance sheet. NOTE 5 -- The Company has adopted the provisions of FASB Statement No. 131, "Disclosures about Segments of an Enterprise and Related Information" ("SFAS No. 131"). SFAS No. 131 requires the utilization of a "management approach" to define and report the financial results of operating segments. The management approach defines operating segments along the lines used by management to assess performance and make operating and resource allocation decisions. The key indicators used by management are revenue and net income before unusual and non-recurring charges and the cumulative effect of accounting change. The effects of unusual and non-recurring items and the cumulative effect of accounting change are excluded since management believes these changes are not indicative of the Company's operating performance. The Company has based its management and reporting structure on four segments: (1) Inpatient and Other Clinical Services, (2) Ambulatory - Surgery Services, (3) Ambulatory - Other Services and (4) Non-Patient Care Services. The inpatient and other clinical services segment includes the operations of inpatient rehabilitation facilities and medical centers, as well as the operations of certain physician practices and other clinical services which are managerially aligned with inpatient services. The ambulatory - surgery services segment includes the operations of ambulatory surgery facilities. The ambulatory - other services segment includes the operations of outpatient rehabilitation facilities and outpatient diagnostic centers. The non-patient care services segment includes the operations of the corporate office, general and administrative costs, non-clinical subsidiaries and other operations that are independent of the inpatient and outpatient services segments. Page 11 Operating results and other financial data are presented for the principal operating segments as follows:
Three Months Ended September 30, ------------------------------------------- 2002 2001 ---------------- --------------- (In thousands) Revenues: Inpatient and other clinical services $ 563,498 $ 520,710 Ambulatory - Surgery services 253,331 234,339 Ambulatory - Other services 267,577 302,409 ---------------- --------------- 1,084,406 1,057,458 Non-patient care services 9,379 18,416 ---------------- --------------- Total revenues $ 1,093,785 $ 1,075,874 ================ =============== Income before unusual and non-recurring items, income taxes and minority interests: Inpatient and other clinical services $ 142,390 $ 99,845 Ambulatory - Surgery services 54,055 53,765 Ambulatory - Other services 18,835 73,723 ---------------- --------------- 215,280 227,333 Non-patient care services (123,004) (74,421) ---------------- --------------- Income before unusual and non-recurring items, income taxes and minority interests 92,276 152,912 Unusual and non-recurring items 25,078 -- ---------------- --------------- Income before income taxes and minority interests $ 117,354 $ 152,912 ================ ===============
Page 12
Nine Months Ended September 30, ---------------- ----------- --------------- 2002 2001 ---------------- --------------- (In thousands) Revenues: Inpatient and other clinical services $ 1,677,965 $ 1,562,353 Ambulatory - Surgery services 773,840 728,811 Ambulatory - Other services 913,055 920,318 ---------------- --------------- 3,364,860 3,211,482 Non-patient care services 22,383 53,842 ---------------- --------------- Total revenues $ 3,387,243 $ 3,265,324 ================ =============== Income before unusual and non-recurring items, income taxes, minority interests and cumulative effect of accounting change: Inpatient and other clinical services $ 436,656 $ 271,089 Ambulatory - Surgery services 197,368 184,691 Ambulatory - Other services 206,633 213,109 ---------------- --------------- 840,657 668,889 Non-patient care services (328,686) (229,657) ---------------- --------------- Income before unusual and non-recurring items, income taxes, minority interests and cumulative effect of accounting change 511,971 439,232 Unusual and non-recurring items (57,146) (139,883) Cumulative effect of accounting change (115,042) -- ---------------- --------------- Income before income taxes and minority interests $ 339,783 $ 299,349 ================ ===============
Unusual and non-recurring items are excluded from the segment presentation because they are not representative of operating data used by the Chief Operation Decision Maker to measure segment operational performance. During the three months and nine months ended September 30, 2002, these items comprised, as applicable, (a) a gain on the early extinguishment of debt in the third quarter and (b) a loss on the early extinguishment of debt and a loss on the the disposition of five nursing home facilites managed for the Company by a third party in the second quarter. During the nine months ended September 30, 2001, these items comprised (a) a loss on the sale of the Company's occupational medicine operations, (b) an increase in bad debt reserves in connection with the sale of the Company's Richmond, Virginia medical center, (c) amounts paid in settlement of a lawsuit with the United States Department of Justice, and (d) a loss on the early termination of a secondary credit facility. NOTE 6 -- During the first nine months of 2002, the Company granted nonqualified stock options to certain Directors, employees and others to purchase 4,343,000 shares of Common Stock at exercise prices ranging from $3.70 to $14.90 per share. NOTE 7 -- In June 2001, the Financial Accounting Standards Board issued FASB Statement No. 141, "Business Combinations" ("SFAS No. 141"), and FASB Statement No. 142, "Goodwill and Other Intangibles" ("SFAS No. 142"). SFAS No. 141 eliminates the use of the pooling method for business combinations and requires that all acquisitions be accounted for under the purchase method. This statement is effective for acquisitions completed after June 30, 2001. SFAS No. 142 requires the periodic testing of goodwill for impairment rather than a monthly amortization of the balance. This testing takes place in two steps: (1) the determination of the fair value of a reporting unit, and (2) the determination of the implied fair value of the goodwill. The Company adopted this statement on January 1, 2002. If the policy had been in effect in the third quarter of 2001, reported net income for that period would have increased by $12,234,000, or $.03 per share (assuming dilution). In July 2002, the Company completed the evaluation of goodwill at December 31, 2001 for impairment under SFAS No. 142 and recognized a goodwill impairment of $83,165,000, net of tax of $31,877,000. The Company utilized independent appraisers in conducting this evaluation. The effects of this impairment are reflected as the cumulative effect of a change in accounting principle in the results of operations for the nine months ended September 30, 2002. Page 13 The following table represents net income and earnings per share results during 1999, 2000 and 2001 as if FAS 142 had been in effect:
TWELVE MONTHS ENDED DECEMBER 31, ----------- ----------- ----------- 2001 2000 1999 ----------- ----------- ----------- Reported net income $ 202,387 $ 278,465 $ 76,517 Add back: Goodwill amortization (net of tax) 46,670 45,304 45,491 ----------- ----------- ----------- Adjusted net income $ 249,057 $ 323,769 $ 122,008 =========== =========== =========== BASIC EARNINGS PER SHARE: Reported net income $ 0.52 $ 0.72 $ 0.19 Add back: Goodwill amortization (net of tax) 0.12 0.12 0.11 ----------- ----------- ----------- Adjusted net income $ 0.64 $ 0.84 $ 0.30 =========== =========== =========== DILUTED EARNINGS PER SHARE: Reported net income $ 0.51 $ 0.71 $ 0.18 Add back: Goodwill amortization (net of tax) 0.11 0.12 0.11 ----------- ----------- ----------- Adjusted net income $ 0.62 $ 0.83 $ 0.29 =========== =========== ===========
Page 14 The following table represents intangibles to be amortized:
Weighted 9/30/02 Average Residual Amortization Gross Accumulated YTD 2002 Amount Period Amount Amortization Expense -------- ------------ ------ ------------ --------- (In Thousands) Non-competes $ 26,679 5 $ 98,569 $ 71,890 $ 10,836 Bond Issue costs 56,623 5 73,412 16,789 8,265 Other 16,080 3 19,255 3,175 2,688 -------- -------- -------- -------- Total $ 99,382 $191,236 $ 91,854 $ 21,789 ======== ======== ======== ========
Estimated Amortization Expense For the Year 2003 2004 2005 2006 2007 -------- -------- -------- -------- -------- (In Thousands) Non-competes $ 10,055 $ 6,384 $ 4,259 $ 1,332 $ 563 Bond Issue costs 9,248 8,843 8,631 8,272 6,575 Other 5,120 3,067 2,283 2,173 1,593 -------- -------- -------- -------- -------- Total $ 24,423 $ 18,294 $ 15,173 $ 11,777 $ 8,731 ======== ======== ======== ======== ========
The following table represents intangibles not to be amortized:
12/31/01 9/30/02 Carrying Disposed of Carrying Amount Acquired Impaired through sale Amount ------------- ------------ ------------- ----------- ------------- (In Thousands) Inpatient and Other Clinical Services $961,163 $37,038 ($20,459) ($16,476) $961,266 Ambulatory - Surgery Services 953,438 448 -- (708) 953,178 Ambulatory - Other Services 702,536 13,209 (94,583) (4) 621,158 Non-patient Care Services 13,393 3,237 -- -- 16,630 ------------- ------------ ------------- ----------- ------------- Total $2,630,530 $53,932 ($115,042) ($17,188) $2,552,232 ============= ============ ============= =========== =============
Page 15 ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS GENERAL We provide outpatient and rehabilitative healthcare services through our inpatient and outpatient rehabilitation facilities, surgery centers, diagnostic centers and medical centers. We have expanded our operations through the acquisition or opening of new facilities and satellite locations and by enhancing our existing operations. As of September 30, 2002, we had approximately 1,795 locations in 50 states, Puerto Rico, the United Kingdom, Australia and Canada, including 1,331 outpatient rehabilitation locations, 118 inpatient rehabilitation facilities, four medical centers, 206 surgery centers and 136 diagnostic centers. FASB Statement ("SFAS") No. 131, "Disclosures about Segments of an Enterprise and Related Information", requires an enterprise to report operating segments based upon the way its operations are managed. This approach defines operating segments along the lines used by management to assess performance and make operating and resource allocation decisions. Based on our management and reporting structure, segment information has been presented for (1) inpatient and other clinical services, (2) ambulatory - surgery services, (3) ambulatory - other services and (4) non-patient care services. The inpatient and other clinical services segment includes the operations of our inpatient rehabilitation facilities and medical centers, as well as the operations of certain physician practices and other clinical services which are managerially aligned with our inpatient services. The ambulatory - surgery services segment includes the operations of our ambulatory surgery facilities. The ambulatory - other services segment includes the operations of our outpatient rehabilitation facilities and outpatient diagnostic centers. The non-patient care services segment includes the operations of our corporate office, general and administrative costs, non-clinical subsidiaries and other operations that are independent of our inpatient and ambulatory services segments. See Note 5 of "Notes to Consolidated Financial Statements" for financial data for each of our operating segments. There are increasing pressures from many payor sources to control healthcare costs and to reduce or limit increases in reimbursement rates for medical services. There can be no assurance that payments under governmental and third-party payor programs will remain at levels comparable to present levels. In addition, there have been, and we expect that there will continue to be, a number of proposals to limit Medicare reimbursement for certain services. As described below, a change in Medicare reimbursement policy relating to the reimbursement for outpatient physical therapy and occupational therapy services had a significant impact on our results of operations in the three months ended September 30, 2002, and will continue to have a significant impact in the foreseeable future. We cannot predict whether others of these proposals will be adopted or, if adopted and implemented, what effect such proposals would have on us. Changes in reimbursement policies or rates by private or governmental payors could have an adverse effect on our future results of operations. Medicare reimbursement for inpatient rehabilitation services is changing from a cost-based reimbursement system to a prospective payment system ("PPS"), with the phase-in of the PPS having begun January 1, 2002. We believe we are well-positioned and well-prepared for the transition and that our emphasis on cost-effective services means that the inpatient rehabilitation PPS will have a positive effect on our results of operations. Our early experience with payments under PPS has been consistent with our internal estimates. However, because implementation of PPS has only recently begun, we cannot be certain that the ultimate impact of the PPS transition will be consistent with our current expectations. In addition, the climate for both governmental and non-governmental reimbursement frequently changes, and future changes in reimbursement rates could have a material effect on our financial condition or results of operations. In many cases, we operate more than one site within a market. In such markets, there is customarily an outpatient center or inpatient facility with associated satellite outpatient locations. For purposes of the following discussion and analysis, same store outpatient rehabilitation operations are measured on locations within markets in which similar operations existed at the end of the period and include the operations of additional outpatient Page 16 rehabilitation locations opened within the same market. New store outpatient rehabilitation operations are measured on locations within new markets. Same store operations in our other business lines are measured based on specific locations. We may, from time to time, close or consolidate similar locations in multi-site markets to obtain efficiencies and respond to changes in demand. CRITICAL ACCOUNTING POLICIES AND ESTIMATES Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. In preparing these financial statements, we are required to make estimates and judgments that affect the reported amounts of our assets, liabilities, revenues and expenses. Those reported amounts could differ, in some cases materially, if we made different estimates and judgments with respect to particular items in our financial statements. We make such estimates and judgments based on our historical experience and on assumptions that we believe are reasonable under the circumstances in an effort to ensure that our financial statements fairly reflect our financial condition and results of operations. We describe some of the most important policies that we follow in making such estimates and judgments below. Revenues and Contractual Reserves Our revenues include net patient service revenues and other operating revenues. Net patient service revenues are reported at estimated net realizable amounts from patients, insurance companies, third-party payors (primarily Medicare and Medicaid) and others for services rendered. Revenues from third-party payors also include estimated retroactive adjustments under reimbursement agreements that are subject to final review and settlement by appropriate authorities. We estimate contractual adjustments from non-governmental third-party payors based on historical experience and the terms of payor contracts. Our reimbursement from governmental third-party payors is based upon cost reports, Medicare and Medicaid payment regulations and other reimbursement mechanisms which require the application and interpretation of complex regulations and policies, and such reimbursement is subject to various levels of review and adjustment by fiscal intermediaries and others, which may affect the final determination of reimbursement. We estimate net realizable amounts from governmental payors based on historical experience and interpretations of such regulations and policies. In the event that final reimbursement differs from our estimates, our actual revenues and net income, and our accounts receivable, could vary from the amounts reported. Allowance for Doubtful Accounts As with any healthcare provider, some of our accounts receivable will ultimately prove uncollectible for various reasons, including the inability of patients or third-party payors to satisfy their financial obligations to us. We estimate allowances for doubtful accounts based on the specific agings and payor classifications at each facility. Net accounts receivable includes only those amounts we estimate to be collectible based on this evaluation. Unforeseen factors, such as the insolvency of third-party payors, could cause our estimate to be inaccurate and could cause our actual results and the amount of our accounts receivable to vary from amounts reported in our financial statements. Impairment of Goodwill Many of our facilities came to us through acquisitions. We determine the amortization period of the cost in excess of net asset value of purchased facilities based on an evaluation of the facts and circumstances of each individual purchase transaction. The evaluation includes an analysis of historic and projected financial performance, an evaluation of the estimated useful life of the buildings and fixed assets acquired, the indefinite useful life of certificates of need and licenses acquired, the competition within local markets, lease terms where applicable, and the legal terms of partnerships where applicable. We utilize independent appraisers and rely on our own management expertise in evaluating each of the factors noted above. With respect to the carrying value of the excess of cost over net asset value of individual purchased facilities and other intangible assets, we determine on a quarterly basis whether an impairment event has occurred by considering factors such as the market value of the asset, a Page 17 significant adverse change in legal factors or in the business climate, adverse action by regulators, a history of operating losses or cash flow losses, or a projection of continuing losses associated with an operating entity. The carrying value of excess cost over net asset value of purchased facilities and other intangible assets will be evaluated if the facts and circumstances suggest that it has been impaired. If this evaluation indicates that the value of the asset will not be recoverable, as determined based on the undiscounted cash flows of the entity acquired over the remaining amortization period, our carrying value of the asset will be reduced to the estimated fair market value. Fair value is determined based on the individual facts and circumstances of the impairment event, and the available information related to it. Such information might include quoted market prices, prices for comparable assets, estimated future cash flows discounted at a rate commensurate with the risks involved, and independent appraisals. For purposes of analyzing impairment, assets of facilities are generally grouped at a market level, which is the lowest level for which there are identifiable cash flows. If we acquired the assets of the facilities being tested as part of a purchase business combination, any goodwill that arose as part of the transaction is included as part of the asset grouping. In July 2001, the Financial Accounting Standards Board issued FASB Statement ("SFAS") No. 142, "Goodwill and Other Intangibles". SFAS No. 142 requires the periodic testing of goodwill for impairment rather than a monthly amortization of the balance. This testing takes place in two steps: (1) the determination of the fair value of a reporting unit, and (2) the determination of the implied fair value of the goodwill. We adopted SFAS No. 142 on January 1, 2002. We determined that if the policy had been in effect in the third quarter of 2001, reported net income for that period would have increased by $12,234,000, or $.03 per share (assuming dilution). In July 2002, we completed the evaluation of goodwill at December 31, 2001 for impairment under SFAS No. 142 and we recognized a goodwill impairment of $83,165,000, net of tax of $31,877,000. We utilized independent appraisers in conducting this evaluation. The effects of this impairment are reflected as the cumulative effect of a change in accounting principle in our results of operations for the nine months ended September 30, 2002. As a result of some of the developments in our business during the third quarter of 2002, which we discuss below, we will be evaluating additional assets for impairment in the fourth quarter of 2002. RESULTS OF OPERATIONS -- THREE MONTHS ENDED SEPTEMBER 30, 2002 Our results of operations in the three months ended September 30, 2002 were significantly affected by a new policy of the Centers for Medicare and Medicaid Services ("CMS"), the government agency that administers the Medicare program, concerning Medicare reimbursement for outpatient physical therapy and occupational therapy services, which went into effect July 1, 2002. Under the new CMS policy, commonly referred to as "Transmittal 1753", providers of outpatient therapy services are required to use the so-called "group therapy" procedure code for billing Medicare when a therapist provides services to more than one patient during a single time period, rather than using individual procedure codes to reflect the specific services provided to the patients. The group therapy code provides for significantly lower reimbursement to therapy providers than do individual procedure codes. During the quarter, we announced that we expected the impact of this change to reduce our pretax earnings by approximately $175,000,000 per year, taking into account our estimates of diminished Medicare revenue and diminished revenue from other payors who follow Medicare payment policies. We also announced a proposed plan to effect a tax-free separation of our surgery center division into a separate public company, a plan which we determined to suspend after the end of the quarter. In addition, during the quarter we were served with several lawsuits alleging violations of the federal securities laws and state corporate laws, and we were notified of a Securities and Exchange Commission investigation relating to our August 27 announcement about the potential impact of Transmittal 1753 on our business. See Item 1, "Legal Proceedings", in Part II of this Quarterly Report on Form 10-Q. As a result, in part, of the demands on management resources brought about by these events, the confusion among our therapists on scheduling and staffing requirements under the new Medicare policy, and the efforts of competing providers to use the substantial adverse publicity surrounding these events to divert business from our facilities, we saw a decline in volumes in our outpatient rehabilitation line of business during the quarter. When compared to the second quarter of 2002, we saw a decrease in reimbursement of approximately $23,000,000 in our outpatient rehabilitation business, primarily attributable to the impact of Transmittal 1753, and an additional $34,000,000 decrease in revenues in our outpatient rehabilitation business attributable to a decline in patient volumes. We also saw an increase of about $39,000,000 in operating unit expenses as compared to the second Page 18 quarter, primarily attributable to field training for therapists in the new Medicare policy, increased recruiting and labor costs, higher insurance premiums and new market initiatives aimed at restoring patient volumes. These factors are reflected in the detailed discussion of our operating results for the quarter that follows. Our operations generated revenues of $1,093,785,000 for the quarter ended September 30, 2002, an increase of $17,911,000, or 1.7%, as compared to the same period in 2001. The increase in revenues is primarily attributable to increases in pricing and volume in our inpatient rehabilitation and surgery divisions. Same store revenues for the quarter ended September 30, 2002 were $1,075,131,000, an increase of $28,949,000, or 2.8%, as compared to the same period in 2001, excluding facilities in operation in 2001 but no longer in operation in 2002. New store revenues were $18,654,000. Revenues generated from patients under the Medicare and Medicaid programs respectively accounted for 37.4% and 2.2% of revenue for the third quarter of 2002, compared to 30.6% and 2.6% for the same period in 2001. The increase in Medicare revenues as a percentage of total revenues is primarily attributable to the transition to PPS of our inpatient rehabilitation facilities and the growth in inpatient rehabilitation revenues during the period. Revenues from any other single third-party payor were not significant in relation to our revenues. During the third quarter of 2002, same store outpatient visits, inpatient discharges, surgical cases and diagnostic cases increased (decreased) by (3.8)%, 10.0%, 5.8% and 5.3%, respectively. Revenue per outpatient visit, inpatient discharge, surgical case and diagnostic case for same store operations increased (decreased) by (12.8)%, 4.4%, 1.6% and (2.7)%, respectively. Operating unit expenses (expenses excluding corporate general and administrative expenses, provision for doubtful accounts, depreciation and amortization, interest expense and impairment charges) were $786,947,000, or 71.9% of revenues, for the quarter ended September 30, 2002, compared to 66.4% of revenues for the third quarter of 2001. Same store operating expenses were $775,581,000, or 72.1% of comparable revenue. New store operating expenses were $11,366,000, or 60.9% of comparable revenue. The increase in operating expenses as a percentage of revenues is attributable to the factors described in the second paragraph above, combined with a decrease in revenues in our outpatient rehabilitation business. Corporate general and administrative expenses increased from $38,958,000 during the 2001 quarter to $55,125,000 during the 2002 quarter. The increase in corporate general and administrative expenses is primarily attributable to increased legal, accounting and professional fees relating to the litigation described in the first paragraph above and the proposed tax-free separation of our surgery center division, as well as corporate-level marketing initiatives aimed at restoring patient volumes. The provision for doubtful accounts was $23,898,000, or 2.2% of revenues, for the third quarter of 2002, compared to $23,980,000, or 2.2% of revenues, for the same period in 2001. Management believes that the allowance for doubtful accounts generated by this provision is adequate to cover any uncollectible receivables. In the third quarter of 2002 we recorded a pretax gain on the early extinguishment of debt in the amount of $25,078,000, resulting from the repurchase of over $444,000,000 of our public debt during the quarter. Depreciation and amortization expense was $79,505,000 for the quarter ended September 30, 2002, compared to $95,790,000 for the same period in 2001. The decrease was primarily attributable to decreased amortization expense due to our adoption of SFAS No. 142. Interest expense was $57,972,000 for the quarter ended September 30, 2002, compared to $50,914,000 for the quarter ended September 30, 2001. The increase is primarily attributable to an increase in our fixed rate debt in 2002 as compared to our floating rate debt in the 2001 quarter. The interest rate on our floating rate debt was lower than that on our fixed rate debt. For the third quarter of 2002, interest income was $1,938,000, compared to $1,430,000 for the third quarter of 2001. Income before income taxes and minority interests for the third quarter of 2002 was $117,354,000, compared to income of $152,912,000 for the same period in 2001. Minority interests decreased income before income taxes by $29,821,000 for the quarter ended September 30, 2002, compared to decreasing income before income taxes by $22,127,000 for the third quarter of 2001. The provision for income taxes for the third quarter of 2002 was $33,919,000, compared to a provision of $51,659,000 for the same period in 2001. The effective tax rate was 38.75% for the quarter ended September 30, 2002 compared to 39.5% for the quarter ended September 30, 2001. Net income for the third quarter of 2002 was $53,614,000, compared to net income of $79,126,000 for the third quarter of 2001. Page 19 SEGMENT-BY-SEGMENT On a segment-by-segment basis, our results of operations for the quarter may be summarized as follows: Inpatient and Other Clinical Services. Revenues in this segment increased over 8% in comparison with the corresponding quarter in 2001. This increase resulted primarily from increased Medicare patient volumes in our inpatient rehabilitation facilities and pricing increases due to the implementation of inpatient rehabilitation PPS, in contrast to the cost-based Medicare reimbursement previously received in our inpatient rehabilitation facilities. Our profitability in this segment has also increased over the corresponding period last year, as a result of increased Medicare revenues and cost-containment initiatives. Ambulatory - Surgery Services. Revenues in this segment increased 8% in comparison with the corresponding quarter in 2001. This increase resulted primarily from our ninth consecutive quarter of same store volume growth and pricing increases in comparison to the 2001 quarter. This volume growth was, in turn, attributable in large part to our success in adding new surgeon partners in our surgery centers as a result of our syndication initiatives. Our profitability in this segment has also increased over the corresponding period last year, as a result of increased revenues and stable levels of variable costs. Ambulatory - Other Services. This segment encompasses the operations of our outpatient rehabilitation and diagnostic imaging facilities. For the reasons discussed at the beginning of this section, revenues and volumes in our outpatient rehabilitation facilities both declined in comparison to the corresponding quarter in 2001. Revenues, volumes and pricing in our diagnostic imaging facilities were all essentially unchanged from the 2001 quarter, making those operations essentially neutral to the performance of this segment in the 2002 quarter. The profitability of this segment declined from 2001 as a result of the diminished performance of our outpatient rehabilitation facilities, for the reasons discussed above. Future profitability trends for this segment will depend in significant part on our ability to successfully respond to the reimbursement changes in our outpatient rehabilitation facilities and restore patient volumes in those facilities. RESULTS OF OPERATIONS -- NINE MONTHS ENDED SEPTEMBER 30, 2002 Our operations generated revenues of $3,387,243,000 for the nine months ended September 30, 2002, an increase of $121,919,000, or 3.7%, as compared to the nine months ended September 30, 2001. Same store revenues were $3,322,196,000, an increase of $202,576,000, or 6.5%, as compared to the same period in 2001, excluding facilities in operation in 2001 but no longer in operation in 2002. New store revenues were $65,047,000. Revenues generated from patients under the Medicare and Medicaid programs respectively accounted for 35.3% and 2.5% of revenue for the first nine months of 2002, compared to 30.5% and 2.6% for the same period in 2001. Revenues from any other single third-party payor were not significant in relation to our revenues. During the first nine months of 2002, same store outpatient visits, inpatient discharges, surgical cases and diagnostic cases increased by 3.6%, 6.5%, 5.7% and 5.0%, respectively. Revenue per outpatient visit, inpatient discharge, surgical case and diagnostic case for same store operations increased (decreased) by (1.0)%, 5.6%, 1.9% and (1.6)%, respectively. Operating unit expenses (expenses excluding corporate general and administrative expenses, provision for doubtful accounts, depreciation and amortization, interest expense and impairment charges) were $2,270,760,000, or 67.0% of revenues, for the nine months ended September 30, 2002, compared to 66.6% of revenues for the first nine months of 2001. Same store operating expenses were $2,225,381,000, or 67.0% of comparable revenue. New store operating expenses were $45,379,000, or 69.8% of comparable revenue. Net income for the nine months ended September 30, 2002, was $135,704,000, compared to $134,489,000 for the same period in 2001. Page 20 LIQUIDITY AND CAPITAL RESOURCES As of September 30, 2002, we had working capital of $1,176,846,000, including cash and marketable securities of $390,441,000. Working capital at December 31, 2001, was $1,377,459,000, including cash and marketable securities of $278,456,000. For the first nine months of 2002, cash provided by operating activities was $595,782,000, compared to $408,684,000 for the same period in 2001. The increase is primarily attributable to a significant reduction of accounts payable in the first quarter of 2001 and reductions in prepaids and other current assets in 2002. Additions to property, plant and equipment and acquisitions accounted for $560,425,000 and $16,907,000, respectively, during the first nine months of 2002. Those same investing activities accounted for $287,535,000 and $5,031,000, respectively, in the same period in 2001. Because of the favorable results we have seen in the early transition to inpatient rehabilitation PPS, we have incurred additional capital expenditures in the first nine months of 2002 in connection with expansion activities at some of our facilities and accelerated development activities. Additionally, we incurred capital expenditures totaling $207,109,000 in the second quarter of 2002 in connection with the purchase of various facilities and properties previously held under tax retention operating leases, as described below. Financing activities provided $178,229,000 and used $87,053,000 during the first nine months of 2002 and 2001, respectively. Net borrowings on long-term debt for the first nine months of 2002 were $209,942,000, versus net principal payments of $103,657,000 for the first nine months of 2001. The table below summarizes our repurchases of outstanding long-term debt obligations in the third quarter of 2002.
Outstanding Principal Outstanding June 30, 2002 Repurchased September 30, 2002 ---------------- ---------------- ------------------- (In thousands) 3.25% Convertible Subordinated Debentures due 2003 $567,750 $213,600 $354,150 6.875% Senior Notes due 2005 250,000 5,000 245,000 7-3/8% Senior Notes due 2006 200,000 19,700 180,300 7.0% Senior Notes due 2008 250,000 -- 250,000 10-3/4% Senior Subordinated Notes due 2008 350,000 30,740 319,260 8-1/2% Senior Notes due 2008 375,000 32,000 343,000 8-3/8% Senior Notes due 2011 400,000 52,300 347,700 7-5/8% Senior Notes due 2012 1,000,000 91,300 908,700 (1) ---------------- ---------------- ------------------- $3,392,750 $444,640 $2,948,110 ================ ================ =================== (1) Amount differs from the amount shown in Note 2 by $22,950,000. In August 2002, we terminated two interest rate swap agreements and recognized proceeds of $22,950,000, which will be amortized over the remaining term of the notes and which is included in the $931,650,000 balance shown in Note 2.
We also used cash to repurchase approximately $5,974,000 in common stock during the third quarter of 2002. Net accounts receivable were $1,028,562,000 at September 30, 2002, compared to $940,414,000 at December 31, 2001. The number of days of average quarterly revenues in ending receivables at September 30, 2002, was 86.5, compared to 77.6 days of average quarterly revenues in ending receivables at December 31, 2001. This increase was primarily attributable to a decline in revenues in the third quarter of 2002 and a diversion of management attention resulting from the events discussed under "Results of Operations--Three Months Ended September 30, 2002", above. The concentration of net accounts receivable from patients, third-party payors, insurance companies and others at September 30, 2002, is consistent with the related concentration of revenues for the period then ended. On June 14, 2002, we entered into a five-year, $1,250,000,000 revolving credit facility (the "2002 Credit Agreement"), which replaced our previous primary credit facility. Interest on the 2002 Credit Agreement is paid based on LIBOR plus a predetermined margin or a base rate. We are required to pay a fee based on the unused portion of the revolving credit facility ranging from .275% to .500% depending on our debt ratings. The principal amount is Page 21 payable in full on June 14, 2007. We have provided a negative pledge on all assets under the 2002 Credit Agreement. At September 30, 2002, we had drawn $150,000,000 under the 2002 Credit Agreement. During 1995 and 1998, we entered into two tax retention operating lease agreements structured through financial institutions for our corporate headquarters building and for nine of our rehabilitation hospitals. In December 2001, we entered into a seven-and-one-half year operating lease agreement to provide for the financing of our replacement medical center in Birmingham, Alabama. On May 29, 2002, we exercised our option to purchase the properties financed under these leases. The total purchase price of these properties was approximately $207,109,000. The table below sets forth certain information concerning amounts due with respect to our long-term debt and various other commitments as of September 30, 2002:
Due Due Due Due 2007 Total 2002 2003-2004 2005-2006 and beyond ------------------------------------------------------------------------------- (In thousands) Long-Term Debt $ 3,173,525 $ 4,604 $ 370,274 $ 439,743 $ 2,358,904 Capital Lease Obligations 21,422 1,545 8,598 5,027 6,252 Noncompete Obligations 16,864 3,065 10,627 3,172 -- Operating Leases 1,161,973 59,026 341,463 219,033 542,451 --------- ------ ------- ------- ------- Total Obligations $ 4,373,784 $68,240 $ 730,962 $ 666,975 $ 2,907,607
Since the end of the quarter, we have used approximately $9,912,000 in available cash to repurchase approximately $10,000,000 in principal amount of our outstanding debt securities. We have been advised by the trustee under the indenture governing our 7-5/8% Senior Notes due 2012 that some bondholders have suggested that the provisions of such indenture relating to transactions with affiliates required us to provide certain documentation in connection with our acquisition of stock from our Chairman of the Board in satisfaction of an outstanding loan. While we do not necessarily believe that such provisions were intended to apply to the transaction, we have advised the trustee of our intention to provide such documentation to it. While the rates of interest payable under our principal credit facility vary depending in part on our debt ratings, we have no credit or lease agreements which provide for the acceleration of maturities or the termination of such agreements based upon any change in our debt ratings. As part of our corporate strategy, we are continually evaluating opportunities for strategic acquisitions and divestitures. We intend to pursue the acquisition or development of additional healthcare operations and other businesses providing complementary services. While it is not possible to estimate precisely the amounts which will actually be expended in the foregoing areas, we anticipate that over the next twelve months, we will spend approximately $100,000,000 to $125,000,000 on maintenance and expansion of our existing facilities and approximately $300,000,000 to $325,000,000 on development activities. Of those amounts, we currently expect that approximately 65% will be required for our inpatient and other clinical services segment (including the construction of our replacement medical center facility in Birmingham, Alabama), approximately 25% for our ambulatory - surgery services segment and approximately 15% for our ambulatory - other services segment. We believe that existing cash, cash flow from operations, and borrowings under existing credit facilities will be sufficient to satisfy our estimated cash requirements for the next twelve months and for the reasonably foreseeable future. Inflation in recent years has not had a significant effect on our business, and is not expected to adversely affect us in the future unless it increases significantly. FORWARD-LOOKING STATEMENTS Statements contained in this Quarterly Report on Form 10-Q which are not historical facts are forward-looking statements. Without limiting the generality of the preceding statement, all statements in this Quarterly Report on Form 10-Q concerning or relating to estimated and projected earnings, margins, costs, expenditures, cash flows, growth rates and financial results are forward-looking statements. In addition, HEALTHSOUTH, through its senior management, from time to time makes forward-looking public statements concerning our expected future operations and performance and other developments. Such forward-looking statements are necessarily estimates based upon current information, involve a number of risks and uncertainties and are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. There can be no assurance that our actual results will not differ materially from the results anticipated in such Page 22 forward-looking statements. While is impossible to identify all such factors, factors which could cause actual results to differ materially from those estimated by us include, but are not limited to, changes in the regulation of the healthcare industry at either or both of the federal and state levels, changes or delays in reimbursement for our services by governmental or private payors, competitive pressures in the healthcare industry and our response thereto, our ability to obtain and retain favorable arrangements with third-party payors, unanticipated delays in the implementation of our strategic initiatives, general conditions in the economy and capital markets, and other factors which may be identified from time to time in our Securities and Exchange Commission filings and other public announcements. ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK We are exposed to market risk related to changes in interest rates. The impact on earnings and value of market risk-sensitive financial instruments (principally marketable security investments and long-term debt) is subject to change as a result of movements in market rate and prices. We use sensitivity analysis models to evaluate these impacts. We do not hold or issue derivative instruments for trading purposes and are not a party to any instruments with leverage features. Our investment in marketable securities was $1,074,000 at September 30, 2002, which represents less than 1% of total assets at that date. These securities are generally short-term, highly liquid instruments and, accordingly, their fair value approximates cost. Earnings on investments in marketable securities are not significant to our results of operations, and therefore any changes in interest rates would have a minimal impact on future pre-tax earnings. Upon application of the proceeds from the sale of our 7-5/8% Notes, all of our long-term indebtedness was subject to fixed rates of interest. In May 2002, we entered into two interest rate swap arrangements in order to improve our mix of fixed and variable rate exposure. Each swap has a notional amount of $250,000,000 and matures 120 months from the date of the original transaction. The notional amounts are used to measure interest to be paid or received and do not represent an amount of exposure to credit loss. In these arrangements, we pay the counterparties a variable rate of interest tied to six-month LIBOR rates, and the counterparties pay us a fixed rate of interest on the notional amount. The variable rates paid by us under these swaps are reset every six months. Thus, these interest rate swaps have the effect of converting $500,000,000 of our fixed-rate debt into variable-rate debt through their maturity dates of June 2012. In August 2002, we terminated both of these interest rate swap arrangements. We realized $22,950,000 in proceeds from the termination, which will be amortized over the remaining term of the agreement. During the third quarter of 2002, we repurchased approximately $444,000,000 in principal of our fixed rate debt securities. We recognized a $25,078,000 gain on early extinguishment of debt, before taxes, on the debt repurchases. We repurchased these securities at a weighted average discount of approximately 7%. With respect to our interest-bearing liabilities, approximately $150,000,000 in long-term debt at September 30, 2002 is subject to variable rates of interest, while the remaining balance in long-term debt of $3,061,811,000 is subject to fixed rates of interest (see Note 2 of "Notes to Consolidated Financial Statements" for further description). This compares to $540,000,000 in long-term debt subject to variable rates of interest and $2,486,947,000 in long-term debt subject to fixed rates of interest at December 31, 2001. The fair value of our total long-term debt, based on discounted cash flow analyses, approximates its carrying value at September 30, 2002 and December 31, 2001 except for our 3.25% Convertible Subordinated Debentures due 2003, 6.875% Senior Notes due 2005, 7.0% Senior Notes due 2008, 10-3/4% Senior Notes due 2008, 8-1/2% Senior Notes due 2008, 8-3/8% Senior Notes due 2011, 7-3/8% Senior Notes due 2006 and 7-5/8% Senior Notes due 2012. The fair value of the 3.25% Convertible Debentures was approximately $326,039,000 and $541,974,000 at September 30, 2002 and December 31, 2001, respectively. The fair value of the 6.875% Senior Notes was approximately $181,913,000 and $250,191,000 at September 30, 2002 and December 31, 2001, respectively. The fair value of the 7% Senior Notes was approximately $168,125,000 and $243,713,000 at September 30, 2002 and December 31, 2001, respectively. The fair value of the 10-3/4% Senior Notes was approximately $222,684,000 and $386,365,000 at September 30, 2002 and December 31, 2001, respectively. The fair value of the 8-1/2% Senior Notes was approximately $258,965,000 and $392,231,000 at September 30, 2002 and December 31, 2001, respectively. The fair value of the 8-3/8% Senior Page 23 Notes was approximately $255,560,000 and $414,940,000 at September 30, 2002 and December 31, 2001, respectively. The fair value of the 7-3/8% Senior Notes was approximately $136,127,000 and $201,350,000 at September 30, 2002 and December 31, 2001, respectively. The fair value of the 7-5/8% Senior Notes was approximately $645,177,000 at September 30, 2002. Based on a hypothetical 1% increase in interest rates, the potential losses in future annual pre-tax earnings would be approximately $1,500,000. The impact of such a change on the carrying value of long-term debt would not be significant. These amounts are determined considering the impact of the hypothetical interest rates on our borrowing cost and long-term debt balances. These analyses do not consider the effects, if any, of the potential changes in the overall level of economic activity that could exist in such an environment. Further, in the event of a change of significant magnitude, management would expect to take actions intended to further mitigate its exposure to such change. Foreign operations, and the related market risks associated with foreign currency, are currently insignificant to our results of operations and financial position. ITEM 4. CONTROLS AND PROCEDURES Within 90 days prior to the date of this report, we carried out an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-14(c) under the Securities Exchange Act of 1934). Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective in timely alerting them to material information relating to us (including our consolidated subsidiaries) required to be included in our periodic Securities and Exchange Commission filings. There have been no significant changes in internal controls or in other factors that could significantly affect these controls subsequent to the date of our most recent evaluation. Page 24 PART II -- OTHER INFORMATION Item 1. LEGAL PROCEEDINGS. 1998 Securities Litigation We were served with various lawsuits filed beginning September 30, 1998 purporting to be class actions under the federal and Alabama securities laws. These lawsuits were filed following a decline in our stock price at the end of the third quarter of 1998. Seven such suits were filed in the United States District Court for the Northern District of Alabama. In January 1999, those suits were ordered to be consolidated under the case style In re HEALTHSOUTH Corporation Securities Litigation, Master File No. CV98-O-2634-S. On April 12, 1999, the plaintiffs filed a consolidated amended complaint against HEALTHSOUTH and certain of our current and former officers and directors alleging that, during the period April 24, 1997 through September 30, 1998, the defendants misrepresented or failed to disclose certain material facts concerning our business and financial condition and the impact of the Balanced Budget Act of 1997 on our operations in order to artificially inflate the price of our common stock and issued or sold shares of such stock during the purported class period, all allegedly in violation of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder. Certain of the named plaintiffs in the consolidated amended complaint also purport to represent separate subclasses consisting of former stockholders of Horizon/CMS Healthcare Corporation and National Surgery Centers, Inc. who received shares of HEALTHSOUTH common stock in connection with our acquisition of those entities and assert additional claims under Section 11 of the Securities Act of 1933 with respect to the registration of securities issued in those acquisitions. Another suit, Peter J. Petrunya v. HEALTHSOUTH Corporation, et al., Civil Action No. 98-05931, was filed in the Circuit Court for Jefferson County, Alabama, alleging that during the period July 16, 1996 through September 30, 1998 the defendants misrepresented or failed to disclose certain material facts concerning the Company's business and financial condition, allegedly in violation of Sections 8-6-17 and 8-6-19 of the Alabama Securities Act. The Petrunya complaint was voluntarily dismissed by the plaintiff without prejudice in January 1999. Additionally, a suit styled Dennis Family Trust v. Richard M. Scrushy, et al., Civil Action No. 98-06592, has been filed in the Circuit Court for Jefferson County, Alabama, purportedly as a derivative action on behalf of HEALTHSOUTH. That suit largely replicates the allegations originally set forth in the individual complaints filed in the federal actions described in the preceding paragraph and alleges that our then-current directors, certain of our former directors and certain of our officers breached their fiduciary duties to HEALTHSOUTH and engaged in other allegedly tortious conduct. The plaintiff in that case has forborne pursuing its claim thus far pending further developments in the federal action, and the defendants have not yet been required to file a responsive pleading in the case. We filed a motion to dismiss the consolidated amended complaint in the federal action in late June 1999. On September 13, 2000, the magistrate judge issued his report and recommendation, recommending that the court dismiss the amended complaint in its entirety, with leave to amend. The plaintiffs objected to that report, and we responded to that objection. On December 20, 2000, without oral argument, the court issued an order rejecting the magistrate judge's report and recommendation and denying our motion to dismiss. We believed that the December 20, 2000 order failed to follow the standards required under the Private Securities Litigation Reform Act of 1995 and Rule 9(b) of the Federal Rules of Civil Procedure, and we filed a motion asking the court to reconsider that order or to certify it for an interlocutory appeal to the United States Eleventh Circuit Court of Appeals. Oral argument on that motion was held on March 2, 2001, and the court denied that motion on March 12, 2001. Accordingly, we filed our answer to the consolidated amended complaint on March 26, 2001. The court held a hearing on the plaintiffs' motion for class certification on April 23, 2002, and requested further briefing on various issues. Those issues have now been briefed, and we are awaiting the court's ruling on class certification, although we do not know when the court will issue its ruling. We believe that all claims asserted in the above suits are without merit, and expect to vigorously defend against such claims. Because such suits remain at an early stage, we cannot currently predict the outcome of any such suits or the magnitude of any potential loss if our defense is unsuccessful. Page 25 Qui Tam/False Claims Act Litigation As previously disclosed, beginning in late December 2001, the United States Department of Justice filed notices of partial intervention in so-called "qui tam" complaints filed against us by private parties under the federal False Claims Act in United States District Courts in Alabama, Florida, New York and Texas. In each case, the Department did not file a complaint in intervention at the time it filed its notice of intervention, and sought and received additional time to file such a complaint. After various motions and procedural actions in the underlying cases, on May 23, 2002, the Department served us with a complaint in intervention in the Texas case, which is styled United States ex rel. James J. Devage v. HEALTHSOUTH Corporation, Civil Action No. SA-98-CA-0372-FB, United States District Court for the Western District of Texas. The complaint alleges that we submitted false claims for reimbursement under Medicare and other federal healthcare programs and federal employee benefit plans in connection with certain physical therapy services provided at our outpatient rehabilitation centers. The complaint does not specify the damages claimed by the Department. The relator has indicated that he is not pursuing any claims other than those in which the Department has intervened. The Alabama, Florida and New York cases have, to the extent not dismissed, been transferred to the Texas court. After resolving various procedural issues among the Department and the various qui tam relators, the court entered a scheduling order requiring us to file responsive pleadings by November 30, 2002. As we have previously noted, we believe that our practices during the period purportedly covered by the complaint were consistent with accepted clinical standards and practices in physical therapy and with existing Medicare regulations. Accordingly, we expect to vigorously defend against the claims asserted in the Department's complaint. However, because of the preliminary status of this litigation, it is not possible to predict at this time the outcome or effect of this litigation or the length of time it will take to resolve this litigation. 2002 Securities and Derivative Litigation We and some of our officers and directors were served with various lawsuits filed beginning August 28, 2002 purporting to be class actions under the federal securities laws. These lawsuits were filed following a decline in our stock price after a public announcement we made on August 27, 2002, concerning our current assessment of the impact on our business of changes in Medicare reimbursement policy for outpatient physical therapy and occupational therapy. To date, approximately 18 such suits have filed in the United States District Court for the Northern District of Alabama. Those suits have been consolidated for administrative purposes under the case style In re HEALTHSOUTH Corporation 2002 Securities Litigation, Consolidated File No. CV-02-BE-2105-S. In general, the complaints allege that, during the period January 14, 2002 through August 27, 2002, the defendants misrepresented or failed to disclose certain material facts concerning our business and financial condition and the impact of the changes in Medicare reimbursement for outpatient therapy services on our operations in order to artificially inflate the price of our common stock, and that some of the individual defendants sold shares of such stock during the purported class period, all allegedly in violation of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder. We filed answers, motions to dismiss and motions for judgment on the pleadings in the individual cases. On November 6, 2002, the court stayed consideration of such motions and any other dispositive matters until a determination of lead counsel in the consolidated cases. The court set a status conference for January 3, 2003, and indicated that it would hear from interested parties on the selection of lead counsel at that time. We believe that all claims asserted in the above suits are without merit, and expect to vigorously defend against such claims. Because such suits remain at an early stage, we cannot currently predict the outcome of any such suits or the magnitude of any potential loss if our defense is unsuccessful. Additionally, beginning August 28, 2002, we and some of our officers and directors (along with third parties in one case) were served with lawsuits purporting to be derivative actions on behalf of HEALTHSOUTH. Four of such lawsuits were filed in the Circuit Court of Jefferson County Alabama (Tucker v. Scrushy, et al., CV-02-5212; Klein v. Chamberlin, et al., CV-02-5662; Lebovitz v. Scrushy, et al., CV-02-6006; and Crooks v. Scrushy, et al., CV-02-6268), two of such lawsuits were filed in the Delaware Chancery Court (Biondi v. Scrushy, et al., C.A. No. 19896NC, and Bachand v. Scrushy, et al., C.A. No. 19968NC), and one of such lawsuits was filed in the United States District Court for the Northern District of Alabama (Vredenburg v. Scrushy, et al., CV-02-C-2565-S). We have not yet been served with this last suit. While the specific allegations vary, in general these cases involve the same allegations as are raised in the federal cases described above and allege that Page 26 certain of our directors and officers breached their fiduciary duties to HEALTHSOUTH and engaged in other allegedly tortuous conduct. Because these cases all purport to assert claims derivatively on behalf of HEALTHSOUTH, we have established a Special Litigation Committee of our Board of Directors to investigate the allegations made in them and determine what, if any, of the claims asserted should appropriately be pursued on behalf of HEALTHSOUTH. We are seeking to have the relevant courts stay further proceedings in these actions pending the determinations of the Special Litigation Committee. Subject to the determinations of the Special Litigation Committee, we believe that all claims asserted in the above suits are without merit, and expect to vigorously defend against such claims. Because such suits remain at an early stage, we cannot currently predict the outcome of any such suits or the magnitude of any potential loss if our defense is unsuccessful. Item 2. CHANGES IN SECURITIES AND USE OF PROCEEDS. (c) Recent Sales of Unregistered Securities We had no unregistered sales of equity securities during the three months ended September 30, 2002. Page 27 Item 6. EXHIBITS AND REPORTS ON FORM 8-K. (a) Exhibits 11. Computation of Income Per Share (unaudited) (b) Reports on Form 8-K During the three months ended September 30, 2002, we filed (i) a Current Report on Form 8-K dated August 14, 2002, furnishing under Item 9 the text of (A) the statements under oath filed by our principal executive officer and principal financial officer with the SEC pursuant to SEC Order 4-460 and (B) the certifications required by our Chief Executive Officer and Chief Financial Officer under 18 U.S.C. ss. 1350; and (ii) a Current Report on Form 8-K dated August 27, 2002, reporting under Item 5 the text of a press release announcing the provision approval by our Board of Directors for the separation of our surgery center operations into a new public company, certain related management changes and our current assessment of the potential adverse impact of changes in Medicare reimbursement for outpatient therapy services. No other items of Part II are applicable to the Registrant for the period covered by this Quarterly Report on Form 10-Q. Page 28 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned thereunto duly authorized. HEALTHSOUTH CORPORATION -------------------------------------- (Registrant) Date: November 14, 2002 WILLIAM T. OWENS -------------------------------------- William T. Owens President and Chief Executive Officer Date: November 14, 2002 MALCOLM E. McVAY -------------------------------------- Malcolm E. McVay Executive Vice President, Chief Financial Officer and Treasurer Page 29 CERTIFICATIONS I, William T. Owens, the principal executive officer of HEALTHSOUTH Corporation, certify that: 1. I have reviewed this quarterly report on Form 10-Q of HEALTHSOUTH Corporation; 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report; 3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report; 4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have: a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared; b) evaluated the effectiveness of the registrant's disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the "Evaluation Date"); and c) presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date; 5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function): a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and 6. The registrant's other certifying officers and I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses. Date: November 14, 2002. WILLIAM T. OWENS ---------------------------- William T. Owens President and Chief Executive Officer HEALTHSOUTH Corporation Page 30 I, Malcolm E. McVay, the principal financial officer of HEALTHSOUTH Corporation, certify that: 1. I have reviewed this quarterly report on Form 10-Q of HEALTHSOUTH Corporation; 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report; 3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report; 4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have: a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared; b) evaluated the effectiveness of the registrant's disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the "Evaluation Date"); and c) presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date; 5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function): a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and 6. The registrant's other certifying officers and I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses. Date: November 14, 2002. MALCOLM E. McVAY ---------------------------- Malcolm E. McVay Executive Vice President and Chief Financial Officer HEALTHSOUTH Corporation Page 31 The undersigned, in his capacity as Chief Executive Officer of HEALTHSOUTH Corporation (the "Company"), hereby certifies as follows with respect to the Company's Quarterly Report on Form 10-Q for the three months ended September 30, 2002 (the "Report"): 1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. ss. 78m or 78o(d)); and 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. This certification is given by the undersigned pursuant to 18 U.S.C. ss. 1350. DATED: November 14, 2002. WILLIAM T. OWENS ---------------------------- William T. Owens President and Chief Executive Officer HEALTHSOUTH Corporation The undersigned, in his capacity as Chief Financial Officer of HEALTHSOUTH Corporation (the "Company"), hereby certifies as follows with respect to the Company's Quarterly Report on Form 10-Q for the three months ended September 30, 2002 (the "Report"): 1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. ss. 78m or 78o(d)); and 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. This certification is given by the undersigned pursuant to 18 U.S.C. ss. 1350. DATED: November 14, 2002. MALCOLM E. McVAY --------------------------------- Malcolm E. McVay Executive Vice President and Chief Financial Officer HEALTHSOUTH Corporation Page 32